Revenue
2016
2017
2018
2019
2020
2021
2022
Solid Biosciences Inc. (SLDB)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $8.1M | $13.6M | $0 | $0 | $0 | $0 | $0 |
| Research & development | $140.3M | $96.4M | $76.6M | $78.4M | $58.7M | $64.9M | $94.7M | $58.0M | $39.9M | $20.1M |
| Operating expenses | $179.2M | $129.7M | $104.3M | $114.5M | $85.9M | $88.4M | $119.3M | $75.7M | $54.9M | $25.6M |
| Operating income | −$179.2M | −$129.7M | −$104.3M | −$106.5M | −$72.3M | −$88.4M | −$119.3M | −$75.7M | −$54.9M | −$25.6M |
| EBITDAderived | −$177.6M | −$127.3M | −$101.7M | −$104.0M | −$69.3M | −$84.5M | −$116.5M | — | — | — |
| Net income | −$174.3M | −$124.7M | −$96.0M | −$86.0M | −$72.2M | −$88.3M | −$117.2M | −$74.8M | −$52.1M | −$21.5M |
| Basic EPSper diluted share | -$1.99 | -$3.06 | -$4.83 | -$10.10 | -$10.14 | -$25.50 | -$2.91 | -$2.25 | -$2.88 | -$10.14 |
| Diluted EPSper diluted share | -$1.99 | -$3.06 | -$4.83 | -$10.10 | -$10.14 | -$25.50 | -$2.91 | -$2.25 | -$2.88 | -$10.14 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 18, 2026Form 4 · 10b5-1 | Cumbo AlexanderPresident and CEO | SellCommon Stock | 16.6K | $5.82 | $96.9K | 235.4K |
| Feb 18, 2026Form 4 · 10b5-1 | Hanrahan JessieChief Regulatory Officer | SellCommon Stock | 4.1K | $5.82 | $24.1K | 74.3K |
| Feb 18, 2026Form 4 · 10b5-1 | Ganot IlanDirector | SellCommon Stock · indirect | 2.7K | $5.82 | $15.5K | 27.5K |
| Feb 18, 2026Form 4 · 10b5-1 | Herzich PaulChief Technology Officer | SellCommon Stock | 3.6K | $5.82 | $21.0K | 72.6K |
| Feb 18, 2026Form 4 · 10b5-1 | Howton David TChief Operating Officer | SellCommon Stock | 7.5K | $5.82 | $43.5K | 105.1K |